The Asia-Pacific neurological disorder drugs market is anticipated to grow significantly over the forecast period (2020-2026). China, India, and Japan, are the key economies contributing to the Asia-Pacific neurological disorder drugs industry growth. The key factors that primarily drive the market growth include the rising prevalence of neurological disorders and key contributions by the key players.
Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in novel drug development and innovation. The rising elder population over 65 years of age is the prime factor that creates scope for the growth of the Asia-Pacific neurological disorder drugs market as this population pool is at high risk of developing neurological disorders such as Parkinson’s Disease, and Alzheimer’s Disease.
To Request a Sample of our Report on Asia-Pacific Neurological Disorder Drugs Market: https://www.omrglobal.com/request-sample/asia-pacific-neurological-disorder-drugs-market
As per the World Bank 2019, Japan has around 28.0% geriatric population, China has 11.4%, Thailand has 12.4%, Singapore has 12.4%, while India has a total of 6.4% population aged 65 and over. As elder people are more prone to diseases, hence, creates a wide scope for the market growth in the region.
Besides, the presence of the key players such as Cadila Healthcare Ltd., Astellas Pharma Ltd., and Cipla Ltd., among others are also contributing to the growth of the market.
Market Coverage
· Market number available for – 2019-2026
· Base year- 2019
· Forecast period- 2020-2026
· Segment Covered- By Disorder Type
· Region Covered- Asia-Pacific
· Competitive Landscape- Cadila Healthcare Ltd., Astellas Pharma Ltd., Cipla Ltd., Sun Pharmaceuticals Industries ltd., Teva Pharmaceuticals Industries Ltd., and Takeda Pharmaceutical Co., Ltd. .
Key questions addressed by the report
· What is the market growth rate?
· Which segment dominates the market in the base year?
· Which segment will project the fastest growth in the market?
· How COVID-19 impacted the market?
· Recovery Timeline
· Deviation from pre-COVID-19
· Most affected segment
· Who is the leader in the market?
· How players are addressing challenges to sustain growth?
· Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A full Report of Asia-Pacific Neurological Disorder Drugs Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-neurological-disorder-drugs-market
Asia-Pacific Neurological Disorder Drugs Market – Segmentation
By Disorder Type
· Epilepsy
· Alzheimer’s Disease
· Parkinson’s Disease
· Multiple Sclerosis
· Huntington Disease
· Others
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
